Restarting subcutaneous infliximab 240 mg after treatment interruption of at least 16 weeks was able to recapture response ...

Increasing number of product approvals by regulatory authorities for the treatment of cancer is expected to drive growth of the subcutaneous drug delivery market. For instance, in February 2019, ...

Halozyme (HALO) is evolving from an ENHANZE royalty story into a diversified subcutaneous drug delivery platform, expanding ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Eisai’s full-throttle development of a subcutaneous sibling to recently approved Alzheimer’s disease drug Leqembi could bear fruit in the coming quarters, with the Biogen-partnered drugmaker aiming to ...

In this exclusive MedPage Today video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations ...

The median total clinic time was not significantly shorter for patients who received subcutaneous trastuzumab/pertuzumab than for those who received the intravenous ...

Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system. After ...

Xeris Biopharma has the green light to take its subcutaneous levothyroxine into phase 2. After talking to the FDA, the company outlined plans to start a midphase trial of the investigational ...

Please provide your email address to receive an email when new articles are posted on . Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs.

MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...

HC Wainwright has initiated coverage on Halozyme Therapeutics Inc HALO with a Buy rating and a price target of $61, citing the company's cutting-edge subcutaneous drug delivery platform. The analysts, ...